NCT00756548

Brief Summary

This is a randomized, parallel, multi-center, single-blind study, comparing BLI850 to an FDA approved bowel preparation in adult subjects undergoing colonoscopy.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
386

participants targeted

Target at P50-P75 for phase_3

Geographic Reach
1 country

12 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2008

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 18, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 22, 2008

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2008

Completed
5.2 years until next milestone

Results Posted

Study results publicly available

December 27, 2013

Completed
Last Updated

December 27, 2013

Status Verified

December 1, 2013

Enrollment Period

3 months

First QC Date

September 18, 2008

Results QC Date

February 19, 2013

Last Update Submit

December 3, 2013

Conditions

Keywords

colonoscopyscreening

Outcome Measures

Primary Outcomes (1)

  • Efficacy - Preparation Quality Using a 4 Point Scale

    Percentage of patients with a successful preparation (cleaning rated as "Good" or "Excellent")

    2 days

Secondary Outcomes (10)

  • Serum Chemistry Results (mEq/L)

    2 days

  • Hematology Results (%)

    2 days

  • Serum Chemistry Results (U/L)

    2 days

  • Serum Chemistry Results (mg/dL)

    2 days

  • Serum Chemistry Results (g/dL)

    2 days

  • +5 more secondary outcomes

Study Arms (2)

1

EXPERIMENTAL

multi-dose preparation for oral administration prior to colonoscopy

Drug: BLI850

2

ACTIVE COMPARATOR

multi-dose preparation for oral administration prior to colonoscopy

Drug: polyethylene glycol 3350 based bowel preparation

Interventions

BLI850DRUG

multi-dose preparation for oral administration prior to colonoscopy

1

multi-dose preparation for oral administration prior to colonoscopy

2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication, including:
  • Evaluation of barium enema results
  • GI bleeding
  • Anemia of unknown etiology
  • Neoplastic disease surveillance
  • Abnormal Endosonography
  • Inflammatory bowel disease
  • Unknown diarrhea or constipation etiology
  • Polypectomy
  • Laser therapy
  • Routine screening
  • At least 18 years of age.
  • Otherwise in good health, as determined by physical exam and medical history.
  • If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, intra-uterine device, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse).
  • Negative urine pregnancy test at screening, if applicable.
  • +1 more criteria

You may not qualify if:

  • Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects who are undergoing colonoscopy for foreign body removal or decompression.
  • Subjects with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.
  • Subjects who had previous significant gastrointestinal surgeries (e.g. colostomy, colectomy, gastric bypass).
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study.
  • Subjects of childbearing potential who refuse a pregnancy test.
  • Subjects who are allergic to any preparation components
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

Advanced Clinical Research Institute

Anaheim, California, 92801, United States

Location

Advanced Clinical Research Institute

Orange, California, 92869, United States

Location

Indiana University Medical Center

Indianapolis, Indiana, 46202, United States

Location

Gastrointestinal Associates

Jackson, Mississippi, 39202, United States

Location

Options Health Research

Tulsa, Oklahoma, 74104, United States

Location

Northwest Gastroenterology Clinic

Portland, Oregon, 97210, United States

Location

Franklin Gastroenterology

Franklin, Tennessee, 37067, United States

Location

Memphis Gastroenterology Group

Germantown, Tennessee, 38138, United States

Location

The Frist Clinic

Nashville, Tennessee, 37203, United States

Location

Houston Medical Research Associates

Houston, Texas, 77090, United States

Location

Charlottesville Medical Research

Charlottesville, Virginia, 22911, United States

Location

Northwest Gastroenterology Associates

Bellevue, Washington, 98004, United States

Location

MeSH Terms

Conditions

Colonic Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Results Point of Contact

Title
John McGowan, Director, Clinical Research
Organization
Braintree Laboratories, Inc.

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 18, 2008

First Posted

September 22, 2008

Study Start

August 1, 2008

Primary Completion

November 1, 2008

Last Updated

December 27, 2013

Results First Posted

December 27, 2013

Record last verified: 2013-12

Locations